Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Filters applied: . Clear all
Page 1
Designing and Building a Portfolio of Individual Support Resources for Physicians.
Brazeau CMLR, Trockel MT, Swensen SJ, Shanafelt TD. Brazeau CMLR, et al. Among authors: shanafelt td. Acad Med. 2023 Oct 1;98(10):1113-1119. doi: 10.1097/ACM.0000000000005276. Epub 2023 May 23. Acad Med. 2023. PMID: 37220390
Coaching involves a certified professional helping an individual identify their values and priorities and consider changes that would allow them to adhere to these more fully, and providing longitudinal support that fosters accountability for action. Individual psychotherapy is a …
Coaching involves a certified professional helping an individual identify their values and priorities and consider changes that would allow …
Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial.
Shanafelt TD, Wang XV, Hanson CA, Paietta EM, O'Brien S, Barrientos J, Jelinek DF, Braggio E, Leis JF, Zhang CC, Coutre SE, Barr PM, Cashen AF, Mato AR, Singh AK, Mullane MP, Little RF, Erba H, Stone RM, Litzow M, Tallman M, Kay NE. Shanafelt TD, et al. Blood. 2022 Jul 14;140(2):112-120. doi: 10.1182/blood.2021014960. Blood. 2022. PMID: 35427411 Free PMC article. Clinical Trial.
Herein, we present the long-term follow-up of the randomized E1912 trial comparing the long-term efficacy of ibrutinib-rituximab (IR) therapy to fludarabine, cyclophosphamide, and rituximab (FCR) and describe the tolerability of continuous ibrutinib. ...
Herein, we present the long-term follow-up of the randomized E1912 trial comparing the long-term efficacy of ibrutinib-rituxim …
Cumulative experience and long term follow-up of pentostatin-based chemoimmunotherapy trials for patients with chronic lymphocytic leukemia.
Kay NE, LaPlant BR, Pettinger AM, Call TG, Leis JF, Ding W, Parikh SA, Conte MJ, Bowen DA, Shanafelt TD. Kay NE, et al. Among authors: shanafelt td. Expert Rev Hematol. 2018 Apr;11(4):337-349. doi: 10.1080/17474086.2018.1442716. Epub 2018 Feb 26. Expert Rev Hematol. 2018. PMID: 29460654 Clinical Trial.
BACKGROUND: 7 regimens of pentostatin based chemoimmunotherapy (CIT) for progressive previously untreated CLL primarily with long term follow-up to update both efficacy and toxicity. RESEARCH DESIGN AND METHODS: Prognostic markers including assessment of IGVH and FISH stat …
BACKGROUND: 7 regimens of pentostatin based chemoimmunotherapy (CIT) for progressive previously untreated CLL primarily with long term …
Time to Second-line Treatment and Subsequent Relative Survival in Older Patients With Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Ammann EM, Shanafelt TD, Larson MC, Wright KB, McDowell BD, Link BK, Chrischilles EA. Ammann EM, et al. Among authors: shanafelt td. Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):e11-e25. doi: 10.1016/j.clml.2017.07.004. Epub 2017 Jul 19. Clin Lymphoma Myeloma Leuk. 2017. PMID: 28802891 Free PMC article.
BACKGROUND: Novel targeted therapies offer excellent short-term outcomes in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL). ...CONCLUSION: Further research is needed to quantify the degree to which targeted therapies provide meaningful …
BACKGROUND: Novel targeted therapies offer excellent short-term outcomes in patients with chronic lymphocytic leukemia and small lymp …
Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: Natural history, clinical correlates, and outcomes.
Parikh SA, Leis JF, Chaffee KG, Call TG, Hanson CA, Ding W, Chanan-Khan AA, Bowen D, Conte M, Schwager S, Slager SL, Van Dyke DL, Jelinek DF, Kay NE, Shanafelt TD. Parikh SA, et al. Among authors: shanafelt td. Cancer. 2015 Sep 1;121(17):2883-91. doi: 10.1002/cncr.29438. Epub 2015 Apr 30. Cancer. 2015. PMID: 25931291 Free PMC article.
Approximately 25% of patients who have CLL with normal IgG levels at diagnosis will subsequently develop hypogammaglobulinemia on long-term follow-up. The presence of hypogammaglobulinemia does not appear to impact overall survival....
Approximately 25% of patients who have CLL with normal IgG levels at diagnosis will subsequently develop hypogammaglobulinemia on long-te …
Risk factors for Richter syndrome in chronic lymphocytic leukemia.
Parikh SA, Shanafelt TD. Parikh SA, et al. Among authors: shanafelt td. Curr Hematol Malig Rep. 2014 Sep;9(3):294-9. doi: 10.1007/s11899-014-0223-4. Curr Hematol Malig Rep. 2014. PMID: 25218362 Review.
Approximately 5-10% of CLL patients develop this complication during long-term follow-up. Traditional risk factors for future RS include clinical (advanced Rai stage), biological (ZAP-70, CD38, CD49d) and genetic (del17p, del11q) characteristics at the time of CLL diagnosi …
Approximately 5-10% of CLL patients develop this complication during long-term follow-up. Traditional risk factors for future RS incl …
Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL).
Shanafelt TD, Ramsay AG, Zent CS, Leis JF, Tun HW, Call TG, LaPlant B, Bowen D, Pettinger A, Jelinek DF, Hanson CA, Kay NE. Shanafelt TD, et al. Blood. 2013 May 16;121(20):4137-41. doi: 10.1182/blood-2012-12-470005. Epub 2013 Mar 14. Blood. 2013. PMID: 23493782 Free article. Clinical Trial.
Commentary: medical student distress: a call to action.
Dyrbye LN, Shanafelt TD. Dyrbye LN, et al. Among authors: shanafelt td. Acad Med. 2011 Jul;86(7):801-3. doi: 10.1097/ACM.0b013e31821da481. Acad Med. 2011. PMID: 21715992
In this issue of Academic Medicine, investigators at the Northwestern University Feinberg School of Medicine explore the benefits of teaching students to employ a cognitive behavioral approach to improving self-care. Beyond its demonstrated short-term efficacy, the approac …
In this issue of Academic Medicine, investigators at the Northwestern University Feinberg School of Medicine explore the benefits of teachin …
Bi-directional activation between mesenchymal stem cells and CLL B-cells: implication for CLL disease progression.
Ding W, Nowakowski GS, Knox TR, Boysen JC, Maas ML, Schwager SM, Wu W, Wellik LE, Dietz AB, Ghosh AK, Secreto CR, Medina KL, Shanafelt TD, Zent CS, Call TG, Kay NE. Ding W, et al. Among authors: shanafelt td. Br J Haematol. 2009 Nov;147(4):471-83. doi: 10.1111/j.1365-2141.2009.07868.x. Epub 2009 Sep 8. Br J Haematol. 2009. PMID: 19751240 Free PMC article.
It was hypothesized that contact between chronic lymphocytic leukaemia (CLL) B-cells and marrow stromal cells impact both cell types. To test this hypothesis, we utilized a long-term primary culture system from bone biopsies that reliably generates a mesenchymal stem cell …
It was hypothesized that contact between chronic lymphocytic leukaemia (CLL) B-cells and marrow stromal cells impact both cell types. To tes …